OBJECTIVES: To determine prevalence, risk factors, and simple identification algorithms for HIV, hepatitis B, and hepatitis C co-infection; factors that may predispose for anti-tuberculosis therapy-induced hepatotoxicity. METHODS: We recruited 300 individuals at in-patient tuberculosis hospitals in three cities in Georgia, administered a behavioral questionnaire, and tested for antibody to HIV, hepatitis C (HCV), hepatitis B core antigen (anti-HBc), and the hepatitis B surface antigen (HBsAg). RESULTS: Of the individuals tested, 0.7% were HIV positive, 4.3% were HBsAg positive, 8.7% were anti-HBc positive, and 12.0% were HCV positive. In multivariable analysis, a history of blood transfusion, injection drug use, and prison were significant independent risk factors for HCV, while a history of blood transfusion, injection drug use, younger age at sexual debut, and a high number of sex partners were significant risk factors for HBV. Three-questionnaire item algorithms predicted HCV serostatus 74.1% of the time and HBV serostatus 85.2% of the time. CONCLUSIONS: Treatment of tuberculosis patients in resource-limited countries with concurrent epidemics of HCV, HBV, and HIV may be associated with significant hepatotoxicity. Serologic screening of tuberculosis patients for HBV, HCV, and HIV or using behavioral algorithms to identify patients in need of intensive monitoring during anti-tuberculosis therapy may reduce this risk.
OBJECTIVES: To determine prevalence, risk factors, and simple identification algorithms for HIV, hepatitis B, and hepatitis C co-infection; factors that may predispose for anti-tuberculosis therapy-induced hepatotoxicity. METHODS: We recruited 300 individuals at in-patienttuberculosis hospitals in three cities in Georgia, administered a behavioral questionnaire, and tested for antibody to HIV, hepatitis C (HCV), hepatitis B core antigen (anti-HBc), and the hepatitis B surface antigen (HBsAg). RESULTS: Of the individuals tested, 0.7% were HIV positive, 4.3% were HBsAg positive, 8.7% were anti-HBc positive, and 12.0% were HCV positive. In multivariable analysis, a history of blood transfusion, injection drug use, and prison were significant independent risk factors for HCV, while a history of blood transfusion, injection drug use, younger age at sexual debut, and a high number of sex partners were significant risk factors for HBV. Three-questionnaire item algorithms predicted HCV serostatus 74.1% of the time and HBV serostatus 85.2% of the time. CONCLUSIONS: Treatment of tuberculosispatients in resource-limited countries with concurrent epidemics of HCV, HBV, and HIV may be associated with significant hepatotoxicity. Serologic screening of tuberculosispatients for HBV, HCV, and HIV or using behavioral algorithms to identify patients in need of intensive monitoring during anti-tuberculosis therapy may reduce this risk.
Authors: Surendra K Sharma; Arumugam Balamurugan; Pradip Kumar Saha; Ravindra M Pandey; Narinder K Mehra Journal: Am J Respir Crit Care Med Date: 2002-10-01 Impact factor: 21.405
Authors: Ketevan Stvilia; Tengiz Tsertsvadze; Lali Sharvadze; Malvina Aladashvili; Carlos del Rio; Mark H Kuniholm; Kenrad E Nelson Journal: J Urban Health Date: 2006-03 Impact factor: 3.671
Authors: D C Richards; T Mikiashvili; J J Parris; E V Kourbatova; J C E Wilson; N Shubladze; T Tsertvadze; G Khechinashvili; C del Rio; H M Blumberg Journal: Int J Tuberc Lung Dis Date: 2006-04 Impact factor: 2.373
Authors: Mauro Schechter; Roberto Zajdenverg; Gisely Falco; Grace Link Barnes; José Cláudio Faulhaber; Jacqueline S Coberly; Richard D Moore; Richard E Chaisson Journal: Am J Respir Crit Care Med Date: 2006-02-10 Impact factor: 21.405
Authors: Hesam Ahmadi Nooredinvand; David W Connell; Mahmoud Asgheddi; Mohammed Abdullah; Marie O'Donoghue; Louise Campbell; Melissa I Wickremasinghe; Ajit Lalvani; Onn Min Kon; Shahid A Khan Journal: World J Gastroenterol Date: 2015-08-07 Impact factor: 5.742
Authors: G Bushnell; N L Stennis; A M Drobnik; D C Proops; S D Ahuja; K Bornschlegel; J Fuld Journal: Epidemiol Infect Date: 2014-11-12 Impact factor: 4.434
Authors: Marco Antonio Moreira Puga; Larissa Melo Bandeira; Mauricio Antonio Pompilio; Grazielli Rocha de Rezende; Luana Silva Soares; Vivianne de Oliveira Langraf de Castro; Tayana Serpa Ortiz Tanaka; Gabriela Alves Cesar; Sandra Maria do Valle Leone de Oliveira; Sheila Araújo Teles; Renata Terumi Shiguematsu Yassuda; Sabrina Moreira Dos Santos Weis-Torres; Sarlete Ferreira Basílio; Julio Croda; Ana Rita Coimbra Motta-Castro Journal: PLoS One Date: 2019-08-22 Impact factor: 3.240